On 19 February 2026, Outlook Therapeutics announced that it has entered into an exclusive commercial distribution agreement with Mediconsult for Lytenava™ (ONS-5010, bevacizumab-vikg/bevacizumab gamma) in Switzerland.
Under the agreement, Mediconsult has exclusive rights to market, import, distribute, commercialise and maintain regulatory affairs for Lytenava™ in Switzerland, whilst Outlook Therapeutics is responsible for the manufacture and supply of the product. Outlook Therapeutics expects Lytenava™ to be available in Switzerland in 2027, subject to regulatory approval.
Lytenava™ is the first and only authorised ophthalmic formulation of bevacizumab in the EU and UK. It received marketing authorisation in the EU in May 2024 and was approved in the UK in July 2024. Lytenava™ was launched in June 2025 in the UK and Germany for treatment of wet AMD. The Scottish Medicines Consortium accepted Lytenava™ for use within NHS Scotland in June 2025.
Outlook Therapeutics received a Complete Response Letter (CRL) from the FDA in December 2025 following a second resubmission of its Biologics Licence Application for Lytenava™. On 11 February 2026, Outlook Therapeutics announced that it had submitted a Type A meeting request with the FDA.
There is at least one ophthalmic bevacizumab biosimilar under development. In March 2025, Intas Pharmaceuticals received approval from India’s CDSCO to conduct Phase 2/3 trials for bevacizumab (solution for intravitreal injection 25mg/mL) in patients with wet AMD.